The defendants named in the suit include Actavis, Amneal Pharmaceuticals, Apotex, Teva, Pfizer and Mylan, among others, who are alleged to have colluded to manipulate prices for widely used generic drugs over a period of several years, according to court documents obtained by Becker’s.
According to the complaint, the defendants’ actions resulted in significant overcharges to Aetna, which serves as a health benefit provider for millions of Americans. Aetna alleged that these price hikes — some exceeding 2,000% — were part of a wider conspiracy to restrict market competition and maintain inflated prices for generic drugs.
The lawsuit details how the companies coordinated the alleged conspiracy through meetings and communications at industry events, where they allegedly fixed prices and allocated market share to avoid competition.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 17–19 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
